Engineering New Biologics, At Scale
Making Complex Applications Possible with Mammalian-Based Expression for New Biologics
With a solid foundation in analytics combined with our best-in-class cell line development (CLD) platform, KBI provides vertically integrated mammalian CDMO services for First in Human (FIH) programs from CLD through to commercial manufacturing.
The increasing complexity of novel therapeutic proteins adds pressure to established modes of expression, including Chinese Hamster Ovary (CHO) cell lines. At KBI Biopharma, as a global partner for mammalian-based biopharmaceutical development and manufacturing, we have engineered this standard workhorse to create our premium proprietary cell line for mammalian-based expression.
Mammalian cells are the gold standard for biologics as a key expression system for the production of new biologics - including therapeutic proteins like monoclonal antibodies (mAbs). CHO cells, specifically, are used for around 70% of recombinant biopharmaceutical proteins. KBI's mammalian CDMO services combine our premium cell line development services with deep expertise in analytical development, process development, and formulation development to create a comprehensive mammalian-based biopharmaceutical development and manufacturing workflow that can solidify mammalian expression for a broad variety of molecule types from CLD to infinity.
A Match for Breakthrough Molecule Types
KBI is redefining how mammalian-based expression is used throughout the development and manufacturing of new biologics, which ultimately strengthens the role of CHO cells in biopharmaceutical protein generation.
More Power To Develop, Manufacture, Repeat
Innovative New Biologics Come To Life With Efficient Workflows
Protein and Process Expertise, Matched to Your Molecule